论文部分内容阅读
目的:观察肾移植术后小剂量霉酚酸酯(MMF)的疗效和安全性。方法:112例肾移植患者随机分为3组,分别予以MMF1.0·d-1、2.0·d-1和硫唑嘌呤(Aza)50-75 mg·d-1,每组均联合应用环孢素(CsA)及泼尼松(Pred),观察肾移植术后6个月内急性排斥反应发生率、移植肾功能及药物副作用。结果:小剂量MMF组严重腹泻比常规剂量组明显下降,两组术后半年急性排斥发生率、移植肾存活率及血肌酐均无统计学差异,而小剂量MMF组术后半年急性排斥发生率明显低于Aza组。结论:小剂量MMF疗效可靠,安全性进一步提高。
Objective: To observe the efficacy and safety of low dose mycophenolate mofetil (MMF) after renal transplantation. Methods: One hundred and twelve patients with renal allograft were randomly divided into 3 groups: MMF 1.0 · d-1, 2.0 · d-1 and Aza 50-75 mg · d-1, CsA and Pred were used to observe the incidence of acute rejection, renal graft function and drug side effects within 6 months after renal transplantation. Results: Severe diarrhea in the low-dose MMF group was significantly lower than that in the conventional dose group. There was no significant difference in the incidence of acute rejection, graft survival and serum creatinine between the two groups after 6 months, but the incidence of acute rejection in the low-dose MMF group Significantly lower than Aza group. Conclusion: The efficacy of low-dose MMF is reliable and the safety is further improved.